Biotech IPOs: Older and Wiser?
This article was originally published in Start Up
Executive Summary
Over the past few months, biotech IPOs have seemed to make a comeback-eight were completed since July, according to Windhover's Strategic Transactions Database, and 5 more have been filed by last count. Perhaps sparking the renewed investor interest: the boom in Internet IPOs, which may have gotten investors comfortable with the idea of valuing companies on their potential to dominate new markets.
You may also be interested in...
Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue
While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.
Biopharma VCs Move to the Middle in 2006
While the venture capital community spent roughly the same in biopharma investments in 2006 as they did in 2005, they put considerably more money into mid-stage companies (Series B and C investments), and slightly less into Series A and mezzanine rounds, than they had in 2005.
Biopharma IPOs Start Swing Back to Nasdaq
The trend of biopharma IPOs eschewing Nasdaq for European and other exchanges reverses modestly in 2006.